Krystal Biotech Stock In The News
KRYS Stock | USD 190.40 8.11 4.45% |
Our overall analysis of Krystal Biotech's news coverage and content from conventional and social sources shows investors' bearish mood towards Krystal Biotech. The specific impact of Krystal Biotech news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Krystal Biotech's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Krystal Biotech headlines in addition to utilizing other, more conventional financial analysis modules. Check out Krystal Biotech Backtesting and Krystal Biotech Hype Analysis. For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.
Krystal |
Krystal Biotech Today Top News and Investor Outlook
Krystal Biotech Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Krystal and other traded companies coverage with news coverage. We help investors stay connected with Krystal headlines for the 25th of November to make an informed investment decision based on correlating the impacts of news items on Krystal Stock performance. Please note that trading solely based on the Krystal Biotech hype is not for everyone as timely availability and quick action are needed to avoid losses.
Krystal Biotech stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Krystal earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Krystal Biotech that are available to investors today. That information is available publicly through Krystal media outlets and privately through word of mouth or via Krystal internal channels. However, regardless of the origin, that massive amount of Krystal data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Krystal Biotech news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Krystal Biotech relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Krystal Biotech's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Krystal Biotech alpha.
Krystal Largest EPS Surprises
Earnings surprises can significantly impact Krystal Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-03-12 | 2017-12-31 | -0.23 | -0.26 | -0.03 | 13 | ||
2019-05-06 | 2019-03-31 | -0.33 | -0.29 | 0.04 | 12 | ||
2019-03-12 | 2018-12-31 | -0.23 | -0.27 | -0.04 | 17 | ||
2019-08-05 | 2019-06-30 | -0.32 | -0.37 | -0.05 | 15 | ||
2021-03-01 | 2020-12-31 | -0.59 | -0.53 | 0.06 | 10 | ||
2020-08-10 | 2020-06-30 | -0.47 | -0.37 | 0.1 | 21 |
Krystal Biotech Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Krystal Biotech Stock. Current markets are strongly bullish. About 89% of major world exchanges and indexes are currently up. See today's market update for more information.21st of November 2024
Jennison Associates LLC Sells 110,333 Shares of Krystal Biotech, Inc. - MarketBeat at news.google.com
15th of November 2024
Redmile Group, LLC Adjusts Stake in Stoke Therapeutics Inc at gurufocus.com
13th of November 2024
FMR LLCs Strategic Acquisition of Krystal Biotech Inc Shares at gurufocus.com
11th of November 2024
Krystal Biotech Scores Relative Strength Rating Upgrade - Investors Business Daily at news.google.com
7th of November 2024
Krystal Biotech Q2 EPS Forecast Increased by William Blair at thelincolnianonline.com
5th of November 2024
Krystal Biotech Inc Q3 2024 Earnings Call Highlights Strong Revenue Growth and ... at gurufocus.com
4th of November 2024
Krystal Biotech, Inc. Beats Q3 Earnings and Revenue Estimates at zacks.com
30th of October 2024
100 Invested In This Stock 5 Years Ago Would Be Worth 400 Today at benzinga.com
23rd of October 2024
PFE Gets FDA Nod for Expanded Use of RSV Vaccine Abrysvo at zacks.com
27th of September 2024
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324 at benzinga.com
9th of September 2024
IMVT Stock Up on Upbeat Data From Graves Disease Study of Batoclimab at zacks.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Krystal Biotech in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Krystal Biotech's short interest history, or implied volatility extrapolated from Krystal Biotech options trading.
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.